Japan approved SIGA Technologies' antiviral treatment TEPOXX for smallpox, mpox, and cowpox, the first orthopoxvirus therapy in Japan. Studies showed efficacy in reducing mortality and viral load. The drug inhibits VP37 protein, slowing virus spread.